Revolution Medicines
Highly Engaged Employees
Highly Engaged EmployeesBusiness Services · California, United States · 501-1,000 Employees
View Company Info for Free
Overview
Headquarters
700 Saginaw Dr, Redwood City, California...Phone Number
(844) 273-8633Website
www.revmed.comRevenue
-Stock Symbol
RVMDIndustry
ZI Rank: 3
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
8
2
2
5
4
3
About Revolution Medicines
Revolution Medicines is a biopharmaceutical company focused on discovering, developing, and delivering targeted therapies for patients with RAS-driven cancers. The company develops innovative RAS(ON) inhibitors using its proprietary tri-complex technology platform, advancing a pipeline of precision oncology medicines through clinical development.Explore more
Revolution Medicines Org Chart
Get the full picture
Sign in to uncover key details.
Show More
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Revolution Medicines your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Revolution Medicines, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Revolution Medicines recently announced quarterly report
Product Launch: Get notified when Revolution Medicines launches new products
Funding: Get notified immidiatlly once Revolution Medicines has new funding data
Website visits: Recent activity has been detected on your website
Click to see if Revolution Medicines had a recent Job posting/layoffs
Check out if Revolution Medicines is spiking on competitors!
Check if Revolution Medicines has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Revolution Medicines
Recommended Actions
Reach out to Masked Content who joined Revolution Medicines as Masked Content
Find 2 more new buyers
Compare Similar Companies to Revolution Medicines
Compare insights from companies similar to Revolution Medicines, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Revolution Medicines is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Revolution Medicines is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Revolution Medicines.
Revolution Medicines financials insights
Gather financial insights about Revolution Medicines, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2016
Series A
$25M
2018
Series B
$56M
2020
Stock Offering
$238M
2021
Stock Offering
$260.9M
Revolution Medicines Tech Stack
A closer look at the technologies used by Revolution Medicines
See more technologies
Most Recent Scoops
Project
Revolution Medicines has announced that the European Medicines Agency's phased review of Draxonracid is underway, with established teams in place in Europe and Japan and capabilities rapidly expanding in preparation for future potential launches, noting that outside the United States, Draxonracid remains investigational and has not yet been approved by any regulatory authorities.
Product Launch, Pharmaceuticals
Project
Laboratory Operations, Medical Research, Clinical Operations
Open Position
Open Position
Open Position
Revolution Medicines News & Media
New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines’ RASONQUE™ (daraxonrasib) in Metastatic Non-Small Cell Lung Cancer
REDWOOD CITY, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers, today announced that The New England Journal of Medicine (NEJM) has published a report describing data from the Phase 1/2 clinical trial evaluating RASONQUE (daraxonrasib), an oral, RAS(ON) multi-selective inhibitor, in patients with previouslRevolution Medicines (RVMD) Made Pancreatic-Cancer History. At $47B Valuation, the Market Already Assumed It
Revolution Medicines, Inc. (NASDAQ:RVMD) touched an all-time high above $224 on August 27, 2026, following FDA approval of Rasonque (daraxonrasib) – the first broad RAS-targeted therapy cleared for metastatic pancreatic cancer. Creating a milestone, the approval came roughly five weeks after filing under the agency’s national priority voucher. The pivotal RASolute 302 trial nearly doubled […]U.S. FDA Approves Revolution Medicines’ RASONQUE™ (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer
This release contains multimedia assets available for download hereBillionaire Stanley Druckenmiller Continues to Load Up on Revolution Medicines. Does He Know Something Wall Street Doesn't?
One of the most successful investors ever really likes this up-and-coming biotech stock.
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Frequently Asked Questions Regarding Revolution Medicines
Sign Up For FreeTo access detailed company insights
Revolution Medicines is a biopharmaceutical company focused on discovering, developing, and delivering targeted therapies for patients with RAS-driven cancers. The company develops innovative RAS(ON) inhibitors using its proprietary tri-complex technology platform, advancing a pipeline of precision oncology medicines through clinical development.... Read More
